Company

Mosanna Therapeutics, Inc.

Mosanna Therapeutics is developing a small-molecule treatment for metabolic obstructive sleep apnea.

About

Founded in 2022, Mosanna Therapeutics develops treatments for metabolic obstructive sleep apnea. Its candidate MOS-118, formerly AVE0118, is a small molecule in development for the condition. In June 2025, the company raised USD 80 million in Series A funding co-led by Pivotal Life Sciences and EQT Life Sciences, with participation from Forbion, Broadview Ventures, Norwest Venture Partners, Forty51 Ventures, High-Tech Gruenderfonds, and Supermoon Capital. The funding will support MOS-118 through Phase 2 clinical trials.

3Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in